Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016

  • ID: 3946392
  • Report
  • 84 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Athersys, Inc.
  • Cell2B S.A.
  • Kiadis Pharma N.V.
  • Novartis AG
  • P2D Bioscience
  • Targazyme, Inc.
  • MORE
Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016, provides an overview of the Hematopoietic Stem Cell Transplantation (Immunology) pipeline landscape.

Hematopoietic stem cell transplantation (HSCT) involves the intravenous (IV) infusion of autologous or allogeneic stem cells to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective. Predisposing risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Treatment includes immunosuppressive drugs.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hematopoietic Stem Cell Transplantation (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hematopoietic Stem Cell Transplantation (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Hematopoietic Stem Cell Transplantation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 1, 3 and 1 respectively for Hematopoietic Stem Cell Transplantation.

Hematopoietic Stem Cell Transplantation (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hematopoietic Stem Cell Transplantation (Immunology).
- The pipeline guide reviews pipeline therapeutics for Hematopoietic Stem Cell Transplantation (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hematopoietic Stem Cell Transplantation (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hematopoietic Stem Cell Transplantation (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hematopoietic Stem Cell Transplantation (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hematopoietic Stem Cell Transplantation (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hematopoietic Stem Cell Transplantation (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Athersys, Inc.
  • Cell2B S.A.
  • Kiadis Pharma N.V.
  • Novartis AG
  • P2D Bioscience
  • Targazyme, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Hematopoietic Stem Cell Transplantation Overview

Therapeutics Development

Pipeline Products for Hematopoietic Stem Cell Transplantation - Overview

Hematopoietic Stem Cell Transplantation - Therapeutics under Development by Companies

Hematopoietic Stem Cell Transplantation - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Hematopoietic Stem Cell Transplantation - Products under Development by Companies

Hematopoietic Stem Cell Transplantation - Companies Involved in Therapeutics Development

Actinium Pharmaceuticals, Inc.

Athersys, Inc.

Bellicum Pharmaceuticals, Inc.

Cell2B S.A.

Celldex Therapeutics, Inc.

Kiadis Pharma N.V.

Novartis AG

P2D Bioscience

Taiga Biotechnologies, Inc.

Targazyme, Inc.

Hematopoietic Stem Cell Transplantation - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ATIR-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPX-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Casin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDX-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CordSafe - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSC-835 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Iomab-B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-05285401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TBX-1400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TXA-127 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TZ-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hematopoietic Stem Cell Transplantation - Dormant Projects

Hematopoietic Stem Cell Transplantation - Discontinued Products

Hematopoietic Stem Cell Transplantation - Product Development Milestones

Featured News & Press Releases

Jun 30, 2016: Kiadis Pharma Orphan Drug Designation for ATIR101 further expanded to include treatment in a hematopoietic stem cell transplantation

May 18, 2016: Kiadis Pharma presents multiple sets of data at the International Society for Cellular Therapy 2016 Annual Meeting

Apr 25, 2016: Actinium to Host Webinar to Discuss SIERRA Trial -- Upcoming Pivotal, Phase 3 Clinical Study for Iomab-B

Apr 06, 2016: Actinium Announces Webinar to Discuss SIERRA Trial -- Upcoming Pivotal, Phase 3 Clinical Study for Iomab-B

Apr 04, 2016: Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR101

Mar 30, 2016: Actinium Receives Orphan Drug Designation From FDA for Iomab-B in Treating Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients

Mar 29, 2016: Kiadis Pharma to host a webcast of the full dataset on the primary endpoint of its single-dose Phase II trial with ATIR101

Mar 08, 2016: Actinium Pharmaceuticals Announces Filing of Provisional Patent Application Related to Commercial Scale Labeling and Processes for Iomab-B

Feb 20, 2016: Celldex Presents Preliminary Cohort Data from Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Harvest at the 2016 BMT Tandem Meeting

Feb 02, 2016: Actinium Pharmaceuticals Announces Participation at Upcoming Annual Meeting of Pre-Eminent Blood and Marrow Transplant Organization

Nov 30, 2015: Actinium to Present on Iomab-B at 8th Annual LD Micro Main Event Conference on December 2, 2015

Apr 23, 2015: Targazyme Announces FDA Concurrence On Targazyme’s Special Protocol Assessment For A Planned Phase 3 Registration Trial For The Treatment Of Patients With Hematologic Malignancie

Mar 17, 2015: Targazyme and M.D. Anderson Cancer Center Receive FDA IND Clearance for Phase I/II Study of TZ101-Treated Regulatory T Cells to Prevent Graft vs Host Disease in Patients Eligible for Hematologic Stem Cell Transplantation

Feb 10, 2015: Targazyme Receives Orphan Drug Designation to TZ101 for Use With Regulatory T Cells to Prevent & Reduce the Severity of Graft Versus Host Disease in Patients Eligible for Hematologic Stem Cell Transplantation

Sep 25, 2014: Celldex Therapeutics Initiates Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Transplantation

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hematopoietic Stem Cell Transplantation, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Hematopoietic Stem Cell Transplantation - Pipeline by Actinium Pharmaceuticals, Inc., H2 2016

Hematopoietic Stem Cell Transplantation - Pipeline by Athersys, Inc., H2 2016

Hematopoietic Stem Cell Transplantation - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016

Hematopoietic Stem Cell Transplantation - Pipeline by Cell2B S.A. , H2 2016

Hematopoietic Stem Cell Transplantation - Pipeline by Celldex Therapeutics, Inc., H2 2016

Hematopoietic Stem Cell Transplantation - Pipeline by Kiadis Pharma N.V., H2 2016

Hematopoietic Stem Cell Transplantation - Pipeline by Novartis AG, H2 2016

Hematopoietic Stem Cell Transplantation - Pipeline by P2D Bioscience, H2 2016

Hematopoietic Stem Cell Transplantation - Pipeline by Taiga Biotechnologies, Inc., H2 2016

Hematopoietic Stem Cell Transplantation - Pipeline by Targazyme, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Hematopoietic Stem Cell Transplantation - Dormant Projects, H2 2016

Hematopoietic Stem Cell Transplantation - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Hematopoietic Stem Cell Transplantation, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Actinium Pharmaceuticals, Inc.
Athersys, Inc.
Bellicum Pharmaceuticals, Inc.
Cell2B S.A.
Celldex Therapeutics, Inc.
Kiadis Pharma N.V.
Novartis AG
P2D Bioscience
Taiga Biotechnologies, Inc.
Targazyme, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll